142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom. (December 2022) - Franks, K.; Ahmed, M.; Smith, D.; Shaw, P.H.; Banna, G.; Cominos, M.; Walther, J.; Talbot, T.; Taylor, P.; Blak, B.; Lindqvist, L.; Paul, S.K.; et al.